On June 26, 2024, the U. S. Food and Drug Administration approved a novel inhaled medication called ensifentrine (Ohtuvayre is the brand name) for the maintenance treatment of patients with COPD. This unique medication has both bronchodilator (opens airways) and anti-inflammatory properties and is delivered in a nebulizer twice a day.